The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Extramedullary disease in multiple myeloma: a systematic literature review
Open accessAbstract
Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. Several different definitions of EMD have been used in the published literature. We advocate that true EMD is restricted to soft-tissue plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD vary according to the phase of MM. At diagnosis, EMD is typically found in skin and soft tissues; at relapse, typical sites involved include liver, kidneys, lymph nodes, central nervous system (CNS), breast, pleura, and pericardium. The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with newly diagnosed MM, the reported incidence ranges from 0.5% to 4.8%, while in relapsed/refractory MM the reported incidence is 3.4 to 14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without soft-tissue plasmacytomas. Among patients with plasmacytomas, those with EMD have poorer outcomes than those with paraskeletal involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement. Available data on treatment outcomes for EMD are derived almost entirely from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected, this is less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 1×
“Published trials of other CAR-T therapies have reported responses in patients with soft-tissue plasmacytomas, but do not report data specifically for patients with EMD [44, 45].”
BackgroundSelf-citationAnti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., Hillengaß, J., Engelhardt, M. M., Usmani, S. Z., Vesole, D. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30189-4 · Cited by 547
Self-citationVarettoni, M., Corso, A., Pica, G.-M., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 489
Usmani, S. Z., Heuck, C. J., Mitchell, A., Szymonifka, J. D., Nair, B. P., Hoering, A., Alsayed, Y. M., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 395
Self-citationBladé, J., de Larrea, C. F., Rosiñol, L., Cibeira, M. T., Jiménez, R., & Powles, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9290 · Cited by 388
Self-citationde Larrea, C. F., Kyle, R. A., Durie, B. G. M., Ludwig, H., Usmani, S. Z., Vesole, D. H., Hájek, R., Miguel, J. F. S., Sezer, O., Sonneveld, P., et al. (2012) · Leukemia · doi:10.1038/leu.2012.336 · Cited by 384
Self-citationCaers, J., Paiva, B., Zamagni, E., Leleu, X. P., Bladé, J., Kristinsson, S. Y., Touzeau, C., Abildgaard, N., Terpos, E., Heusschen, R., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0549-1 · Cited by 338
Self-citation
Cited by
Sorted by citations
Items 301–319 of 319
Imaging approach to synchronous bone and soft tissue lesions
Gaitán, K. C., Giotas, V., Haris, M. R., Jacob, J., Thaker, S., & Gupta, H. (2026) · British Journal of Radiology · doi:10.1093/bjr/tqag216
Factors Affecting Prognosis in Patients with Extramedullary Myeloma: A Single-Center Experience
Bozan, E., Yaman, S., Bozan, G., Durmuş, M. E., Candır, B. A., Hatipoglu, U., Boral, B., İskender, D., Ulu, B. U., Yiğenoğlu, T. N., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176765
Ahadzade, A., Elverdi, T., Küçükyurt, S., Erçalışkan, A., Özkan, T., Demiröz, A. S., Özmen, D., Yılmaz, U., Eşkazan, A. E., Ar, M. C., et al. (2026) · Current Research in Translational Medicine · doi:10.1016/j.retram.2026.103605
Yokoyama, D., Minakata, D., Fujiwara, S., Honda, S., Tominaga, R., Noguchi, A., Furuki, S., Koyama, S., Murahashi, R., Nakashima, H., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2723847
Li, Y., Shi, L., Yan, W., Liu, Y., Cui, J., Xu, J., Zhou, J., Du, C., Deng, S., Sui, W., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03133-8
Wei, Y., Yang, X., Zheng, Y., & Zhang, D. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261488942
An Uncommon Twist: Intussusception as a Rare Manifestation of Extramedullary Myeloma
Quinn, E., Murphy, A. E., Duggan, W. P., DelaHarpe Golden, P., & Kavanagh, D. O. (2026) · Case Reports in Surgery · doi:10.1155/cris/1872149
Chadli, S., Mouna, M., Khibri, H., Ammouri, W., Moatassim, N., Retal, H., Tazi, Z. M., & Harmouche, H. (2026) · Oxford Medical Case Reports · doi:10.1093/omcr/omag176
Asad, A. B., Younes, S., Al-Mafrachi, D., Fang, P. Q., & Al-Zubidi, N. S. (2026) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002542
Multiple Myeloma Presenting as a Pancoast-Like Tumor: A Diagnostic Challenge
Lúcio, M. J., Matos, C., Carvalho, L., Saldanha, T., & Correia, J. M. (2026) · Cureus · doi:10.7759/cureus.117093
Beider, K., Ostrovsky, O., & Nagler, A. (2026) · Cancers · doi:10.3390/cancers18193158
Chuang, S., & Chang, C.-C. (2026) · Blood Research · doi:10.1007/s44313-026-00179-6
Dual antigen targeting in extramedullary multiple myeloma
Javed, B., & Shaji, K. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2746598
Isea, A. E. B., Wakfie-Corieh, C. G., Iñigo, B., Cerrato, E. O., Melo, A., & Martin, M. N. C. (2026) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2026.500360
Rondón-Carvajal, J., Useche-Henao, E. M., Espir-Sánchez, M. J., & Agudelo-Zapata, Y. (2026) · Cureus · doi:10.7759/cureus.118321
Buchta, M., Hořava, V., & Mihályová, J. (2026) · Urologie pro praxi · doi:10.36290/uro.2025.082
Soomro, M. A., Khaliq, A., Abid, M. B., Paul, B., Atrash, S., Shaikh, H. G., Mazloom, A., Alkharabsheh, O. A., Mewawalla, P., Shah, M. R., et al. (2026) · Current Oncology · doi:10.3390/curroncol33110642
Rana, M. H., Elkishik, Z. A., Minhas, U. A., Malik, S., Aslam, T., Saadeldin, K., & Eldin, M. S. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-277613
Metadata
- Authors
- Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., & Richardson, P.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Centre Hospitalier Universitaire de Liège (BE)
- Jagiellonian University (PL)
- Nantes Université (FR)
- Universitätsklinikum Würzburg (DE)
- Levine Cancer Institute (US)
- Istituto di Ematologia di Bologna (IT)
- Harvard University (US)
- Corresponding author
- Bladé, Joan
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2022-03-21
- Volume
- 12
- Issue
- 3
- Pages
- 45-45
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8938478
- OpenAlex
- W4220896277
- Cited by
- 319
- References
- 56
- Citations by year
- 2026: 79 · 2025: 107 · 2024: 73 · 2023: 44 · 2022: 14
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion, cc-by)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- extramedullary disease, multiple myeloma, soft tissue plasmacytoma, hematogenous spread, relapsed/refractory multiple myeloma, central nervous system involvement, leptomeningeal involvement, prognosis, treatment outcomes
- MeSH terms
- Humans, Multiple Myeloma, Neoplasm Recurrence, Local, Plasmacytoma, Prospective Studies, Retrospective Studies, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
